RenovoRx Q3 2026 net loss widens 25% year over year to $3.65 million
RNXT•RenovoRx reported a third-quarter 2026 net loss of $3.65 million, up 25% year over year, as revenue rose to $1.07 million. Full-year revenue guidance remained $3.75 million to $4.25 million.
1. Quarterly results
RenovoRx’s third-quarter 2026 net loss widened 25% year over year to $3.65 million. Revenue rose year over year to $1.07 million, driven by continued RenovoCath commercialization and expanding adoption across U.S. cancer centers. Active commercial cancer center customers increased 24% from the second quarter to 26 at quarter-end.
2. Trial and guidance
The Phase III TIGeR-PaC trial reached full enrollment in August 2026, with initial top-line data expected in the second half of 2027. Full-year 2026 revenue guidance remained unchanged at $3.75 million to $4.25 million.
